Tema Etfs LLC Makes New $1.20 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Tema Etfs LLC acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 44,343 shares of the company's stock, valued at approximately $1,203,000. Tema Etfs LLC owned 0.08% of Structure Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. ANTIPODES PARTNERS Ltd lifted its position in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares during the period. Virtus ETF Advisers LLC raised its holdings in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares in the last quarter. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after buying an additional 953 shares during the period. Tower Research Capital LLC TRC boosted its stake in Structure Therapeutics by 673.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after buying an additional 3,549 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in Structure Therapeutics in the fourth quarter valued at $113,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GPCR. HC Wainwright cut their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a report on Monday, May 12th. William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Finally, Citigroup began coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $79.86.

Structure Therapeutics Stock Performance

GPCR traded down $0.39 during midday trading on Friday, hitting $24.27. The company had a trading volume of 108,639 shares, compared to its average volume of 929,295. Structure Therapeutics Inc. has a twelve month low of $13.22 and a twelve month high of $62.74. The firm's 50-day simple moving average is $21.46 and its 200-day simple moving average is $26.13. The company has a market capitalization of $1.39 billion, a PE ratio of -32.79 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.